Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 09/24 10:59:44 am
28.72 DKK   -2.71%
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/16European ADRs Move Lower in Thursday Trading
MT
09/15European ADRs Modestly Higher Wednesday as Energy Stocks Rally
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
28.92(c) 28.2(c) 29.3(c) 29.52(c) 28.72(c) Last
159 015 149 673 64 163 58 038 82 664 Volume
-11.83% -2.49% +3.90% +0.75% -2.71% Change
More quotes
Estimated financial data (e)
Sales 2021 24,2 M 3,81 M 3,81 M
Net income 2021 -628 M -99,1 M -99,1 M
Net cash position 2021 122 M 19,2 M 19,2 M
P/E ratio 2021 -1,87x
Yield 2021 -
Sales 2022 41,6 M 6,55 M 6,55 M
Net income 2022 -365 M -57,5 M -57,5 M
Net Debt 2022 124 M 19,5 M 19,5 M
P/E ratio 2022 -5,59x
Yield 2022 -
Capitalization 1 004 M 158 M 158 M
EV / Sales 2021 36,5x
EV / Sales 2022 27,1x
Nbr of Employees 180
Free-Float 98,6%
More Financials
Company
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other... 
More about the company
Ratings of Orphazyme A/S
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ORPHAZYME A/S
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/16European ADRs Move Lower in Thursday Trading
MT
09/15European ADRs Modestly Higher Wednesday as Energy Stocks Rally
MT
09/06ORPHAZYME A/S : Final Deadline for Investors with Losses Exceeding $500K to Actively Parti..
BU
09/03THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the Class Acti..
BU
08/31ORPHAZYME A/S : Interim Report First Half 2021 Investor Call.pdf
PU
08/31ORPHAZYME A/S : Interim Report First Half 2021 (Form 6-K)
PU
08/31ORPHAZYME A/S : Interim Report First Half 2021
PU
08/31ORPHAZYME A/S : reports business highlights and financial results in Interim Report First ..
AQ
08/31Orphazyme A/S Maintains its Outlook for the Full Year 2021
CI
08/31Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/30European ADRs Move Slightly Higher in Monday Trading
MT
08/27European ADRs Rise Nearly 1% Friday Morning
MT
08/25Orphazyme to host Interim Report First Half 2021 investor calláon August 31, 2021
GL
08/24European ADRs Marginally Lower Tuesday as Rio Tinto, Carnival Advance
MT
More news
News in other languages on ORPHAZYME A/S
09/23Les ADR européens sont en forte hausse ce jeudi
09/16Les ADR européens en baisse jeudi
09/15Hausse modérée des ADR européens mercredi, avec le rallye des valeurs énergétiques
08/31Orphazyme A/S maintient ses perspectives pour l'ensemble de l'année 2021
08/30Les ADR européens progressent légèrement dans les échanges de lundi
More news
Analyst Recommendations on ORPHAZYME A/S
More recommendations
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | ORPHA | DK0060910917 | MarketScreener
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 28,72 DKK
Average target price 60,50 DKK
Spread / Average Target 111%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus BornŠs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-57.20%158
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634